Gara Jalqabaatti › Dukkana Dhiigaa › Texas › Houston
Qorannoo klinikaalii Dukkana Dhiigaa Houston, TX keessatti
Qorannoo 46 Dukkana Dhiigaa f Houston fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Namoota walitti qabaa jiraSadarkaa 1
- UT MD Anderson Cancer Center, Houston
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Namoota walitti qabaa jiraSadarkaa 3
- University of Texas MD Anderson Cancer Center ( Site 0007), Houston
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
- UT MD Anderson Cancer Center, Houston
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Namoota walitti qabaa jiraQorannoo ilaalaa
- Texas Children's Hospital, Houston
A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
Namoota walitti qabaa jiraSadarkaa 1
- MD Anderson Cancer Center - University of Texas, Houston
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
Namoota walitti qabaa jiraSadarkaa 3
- Quetzal Site 6, Houston
Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease
Namoota walitti qabaa jiraSadarkaa jalqabaa 1
- M D Anderson Cancer Center, Houston
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Namoota walitti qabaa jiraSadarkaa 3
- The University of Texas MD Anderson Cancer Center, Houston
Bone Marrow Imaging and Clinical Outcomes Across Hematologic, Oncologic, and Other Relevant Conditions
Namoota walitti qabaa jiraQorannoo ilaalaa
- UT MD Anderson Cancer Center, Houston
Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)
Namoota walitti qabaa jiraSadarkaa 1
- Texas Children's Hospital, Houston
- The Methodist Hospital, Houston
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Namoota walitti qabaa jiraSadarkaa 1
- Md Anderson Cancer Center, Houston
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Namoota walitti qabaa jiraSadarkaa 2
- The University of Texas MD Anderson Cancer Center, Houston
Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure
Namoota walitti qabaa jira
- M D Anderson Cancer Center, Houston
Impact of Project ECHO on Improving the Quality of Palliative Care in Patients With Advanced Cancer and Their Caregivers in Underserved Areas of Kenya, Nigeria, Ghana, South Africa, India, and Ethiopia
Namoota walitti qabaa jiraSadarkaa 2Hojjettoota fayyaa simatamoo
- M D Anderson Cancer Center, Houston
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Namoota walitti qabaa jiraSadarkaa 1
- M D Anderson Cancer Center, Houston
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Namoota walitti qabaa jiraSadarkaa 1/2
- MD Anderson, Houston
Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program
Namoota walitti qabaa jiraQorannoo ilaalaa
- M D Anderson Cancer Center, Houston
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Namoota walitti qabaa jiraSadarkaa 3
- University of Texas, Houston
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Namoota walitti qabaa jiraSadarkaa 1
- MD Anderson Cancer Center, Houston
Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances
Namoota walitti qabaa jiraSadarkaa 1/2
- M D Anderson Cancer Center, Houston
Alteplase Through an Indwelling Pleural Catheter for the Management of Symptomatic Septated Malignant Pleural Effusion
Namoota walitti qabaa jiraSadarkaa jalqabaa 1
- M D Anderson Cancer Center, Houston
Expressive Writing for the Management of Stress in Cancer Survivors
Namoota walitti qabaa jira
- M D Anderson Cancer Center, Houston
Complications and Clinical Response in Cancer Patients Treated With Anti-VEGF-Related Therapies
Namoota walitti qabaa jiraQorannoo ilaalaa
- M D Anderson Cancer Center, Houston
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
Namoota walitti qabaa jiraSadarkaa 1
- MD Anderson Cancer Center, Houston
The Impact of COVID-19 on Pulmonary Procedures
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
- M D Anderson Cancer Center, Houston
PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)
Namoota walitti qabaa jiraSadarkaa 2
- University of Texas MD Anderson MD Anderson Cancer Center, Houston
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
Namoota walitti qabaa jiraSadarkaa 1
- The University of TX MD Anderson Cancer Center, Houston
Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients
Namoota walitti qabaa jiraSadarkaa 2
- M D Anderson Cancer Center, Houston
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Namoota walitti qabaa jiraQorannoo ilaalaa
- M.D. Anderson Cancer Center, Houston
- Texas Children's Hospital - Baylor Medical Center, Houston
Improving Comprehensive Care of Cancer Patients
Namoota walitti qabaa jiraHojjettoota fayyaa simatamoo
- Baylor College of Medicine, Houston
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Namoota walitti qabaa jiraSadarkaa 1
- MD Anderson Cancer Center, Houston
Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy
Namoota walitti qabaa jiraQorannoo ilaalaa
- M D Anderson Cancer Center, Houston
The Effect of COVID-19 Pandemic on Adolescent and Young Adult Cancer Patients and Survivors
Namoota walitti qabaa jiraQorannoo ilaalaa
- M D Anderson Cancer Center, Houston
Formulating Expert Consensus Guidelines in Cancer Care Using the Delphi Method
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
- M D Anderson Cancer Center, Houston
Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
Namoota walitti qabaa jiraQorannoo ilaalaa
- M D Anderson Cancer Center, Houston
Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
Namoota walitti qabaa jiraSadarkaa 2
- M D Anderson Cancer Center, Houston
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Namoota walitti qabaa jiraSadarkaa 1
- MD Anderson Cancer Center, Houston
A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients
Namoota walitti qabaa jiraSadarkaa 3
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Exercise Program (TEAM Me) for the Improvement of Movement and Mobility in Pediatric and Adolescent and Young Adult Patients With Cancer Undergoing a Blood Stem Cell Transplant
Namoota walitti qabaa jira
- M D Anderson Cancer Center, Houston
Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation
Namoota walitti qabaa jiraSadarkaa 2
- The University of Texas M. D. Anderson Cancer Center, Houston
Outcomes After Chimeric Antigen Receptor Therapy and Radiation Therapy for Hematologic Malignancies
Namoota walitti qabaa jiraQorannoo ilaalaa
- M D Anderson Cancer Center, Houston
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Namoota walitti qabaa jiraSadarkaa 1/2
- The University of Texas MD Anderson Cancer Center, Houston
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Namoota walitti qabaa jiraSadarkaa 1
- MD Anderson Cancer Center, Houston
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Namoota walitti qabaa jiraSadarkaa 1/2
- University of Texas MD Anderson Cancer Center, Houston
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Namoota walitti qabaa jiraSadarkaa 1
- Texas Children's Hospital/Baylor College of Medicine, Houston
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
Namoota walitti qabaa jiraSadarkaa 1
- MD Anderson Cancer Center, Houston
Qorannoo Dukkana Dhiigaa magaalota biroo keessatti
- New York City, NYQorannoo 26
- Boston, MAQorannoo 25
- Washington, DCQorannoo 19
- Seattle, WAQorannoo 18
- Baltimore, MDQorannoo 18
- Los Angeles, CAQorannoo 17
- Durham, NCQorannoo 16
- Chicago, ILQorannoo 15
- Philadelphia, PAQorannoo 14
- Columbus, OHQorannoo 13
- Edison, NJQorannoo 13
- Nashville, TNQorannoo 13
Qorannoo biroo Houston keessatti
- Kansara Qara'a Non-Small CellQorannoo 145
- Saree OljooQorannoo 126
- Saree (Gosoota Hunda)Qorannoo 121
- Kansara MetastatikiiQorannoo 104
- Kansarii ColorectalQorannoo 102
- Kansarii OvariiQorannoo 89
- Leukemia Myeloidii HamaaQorannoo 85
- Dhibee QaraQorannoo 78
- Kansarii ProstateQorannoo 76
- Kansa EndometiriyaaliiQorannoo 68
- Kansarii PancreasQorannoo 61
- MelanomaQorannoo 59
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.